Pharma News | Biotech News | Global Pharma

With exclusive access to key industry decision makers and best-in-class proprietary data, Scrip empowers you to understand the news behind the news.

How it helps

Use Scrip’s focus on the strategic implications of global pharma news to fully understand what worldwide developments in the industry mean for your business.

With end-to-end coverage encompassing the whole of the drug discovery, development, and product life cycle value chain, Scrip delivers analysis, news and insights across multiple therapy areas and product types.

How it works

Scrip provides business-critical market and company intelligence from our global network of analysts, journalists and key opinion leaders. They cover companies across the industry, from biotech start-ups to multinational giants such as Pfizer, Sanofi and Shire, and report on fields including cardiovascular, diabetes, dermatology, influenza, and oncology.

Scrip gives you access to the latest licensing opportunities, partnership deals, R&D activity, market access insights and company developments. Your subscription also includes the Scrip 100 annual review, which tracks and analyzes the performance of over 600 companies and provides additional insights into pharma industry topics that impact your business.

Scrip

Report: Women Eschew Life Science Companies That Lack Female Leadership

By Mandy Jackson 23 Sep 2017

MassBio and Liftstream partnered on a report about women's, men's and companies' views on gender diversity

Scrip

Gates Foundation’s $40m Incentivizes Cancer Specialist Immunocore To Develop TB, HIV Drugs

By Lucie Ell 23 Sep 2017

Oxford, UK-based Immunocore, which is developing immunotherapies against cancer

Scrip

APOLLO Success Clears Alnylam For Lift-Off

By Joseph Haas 23 Sep 2017

Phase III APOLLO results finally give the beleagured firm the first late-stage success

Scrip

Teva Offloads Women's Health Business To Two Firms For $1.38Bn

By Jessica Merrill 21 Sep 2017

The generic drug maker signed two deals to divest its women's health business

Scrip

Scrip Awards 2017

20 Sep 2017

Find out more about the Scrip Awards by watching the video.

Scrip

Amicus Drops Epidermolysis Bullosa Candidate Following Phase III Failure

By Joseph Haas 16 Sep 2017

CEO Crowley points to the need to focus on a pair of Fabry candidates, including the pending NDA for migalastat, and notes that other companies have reached Phase III in EB.

Scrip

Merck & Co Cancer Chief Reflects on 'Foundational' Keytruda

By Kevin Grogan 16 Sep 2017

Roger Dansey, head of Merck's clinical development in oncology, tells Scrip that the Keynote clinical program for the blockbuster PD-1 inhibitor continues to hit endpoints.

Scrip

With J&J’s Departure From HCV, Gilead Stands Alone In ‘Nuc’ Field

By Joseph Haas 16 Sep 2017

J&J is the latest firm to back away from the hepatitis C field, reflecting the dominant position Gilead has built with its sofosbuvir franchise

Scrip, In Vivo, Pink Sheet, Medtech Insight

What actually keeps biopharma execs up at night?

07 Sep 2017

What actually keeps biopharma execs up at night? Take our quiz to find out.

Scrip

Novartis CEO-Designate Set To Bring More Automation To Drug Discovery

By Sten Stovall 05 Sep 2017

Vasant Narasimhan, who is replacing Joseph Jimenez as Novartis' CEO next year, is an advocate of automation and artificial intelligence in future drug discovery.

Scrip

CARsgen Eyes US Filing For Anti-Claudin18.2 CAR-T Therapy

By Ying Huang 05 Sep 2017

Chinese start-up CARsgen Therapeutics hopes to launch trials in the US for its first-in-class anti-claudin18.2 CAR-T cell therapy.

Scrip

Medicines Company Gets Aggressive With Inclisiran Phase III Plans

By Alex Shimmings 01 Sep 2017

European Society of Cardiology have encouraged The Medicines Company to take an "aggressive" approach to its Phase III plans for the novel PCSK9 synthesis inhibitor.

Scrip

Jazz Raising Hematology/Oncology Reach Further With ImmunoGen Deal

By Sten Stovall 01 Sep 2017

Ireland-based Jazz Pharma is extending its shift away from specialty pharma with an option-based deal with ImmunoGen involving three antibody-drug conjugate programs.

Scrip

Precision Medicine: Despite Gains, Optimum Use Far From Reached

By Mandy Jackson 31 Aug 2017

Progress has been made in areas such as lung and breast cancer, but panelists at a recent conference noted there are many efficiencies yet to be realized.

Scrip

Gilead Makes Cell Therapy The Base Of Its Oncology Platform With Kite Buy

By Mandy Jackson 31 Aug 2017

Gilead's Kite acquisition may finally have appeased investors' thirst for a major deal with a transaction that will diversify revenue and expand its oncology portfolio.